National Emerging Infectious Diseases Laboratories Operations

国家新发传染病实验室运作

• 批准号: 10663821
• 负责人: Nancy Jean Sullivan
• 金额: $ 1150万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663821
• 关键词: Acceleration; Advanced Development; Animal Model; Animals; Area; Attention; Basic Science; Biology; Boston; Categories; Clinical Research; Collaborations; Communities; Comparative Study; Complement; Containment; Development; Diagnosis; Diagnostic; Diagnostic tests; Discipline; Emergency Situation; Emerging Communicable Diseases; Engineering; Environment; Environmental Health; Event; Faculty; Faculty Recruitment; Goals; Health; Human; Human Resources; Infectious Diseases Research; Information Technology; International; Investigation; Laboratories; Medical; Medical center; Methodology; Mission; Modeling; Pathogenesis; Pathogenicity; Physiological; Process; Public Health; Public Health Schools; Reporting; Research; Research Personnel; Research Support; Safety; Science; Scientist; Secure; Security; Services; Strategic Planning; Teaching Hospitals; Therapeutic; Training; Training and Education; Translational Research; United States; Universities; Vaccines; Veterinary Pathology; biodefense; biosecurity; emerging pathogen; experience; flexibility; human disease; improved; innovation; insight; interest; medical schools; microbial; new technology; next generation; operation; pandemic pathogen; pandemic potential; pathogen; pre-clinical research; prevent; programs; recruit; research and development; research facility; response; skills; tool; vaccine evaluation

Overall Abstract The National Biocontainment Laboratory (NBL) at Boston University (BU) is known as the National Emerging Infectious Diseases Laboratories (NEIDL). It is owned and operated by BU and is located on the Boston University Medical Campus (BUMC) adjacent to the BU School of Medicine, the Graduate Sciences program, the BU School of Public Health, and the affiliated teaching hospital, Boston Medical Center. The NEIDL's missions are: (1) To perform innovative basic, translational and clinical research on emerging infectious diseases in order to develop diagnostic tests, treatments and vaccines to promote the public's health; (2) To provide training in these areas of research and to support a national response in the event of a biodefense emergency; and (3) To establish a research facility with the highest attention to community and laboratory safety and security. In order to successfully achieve these missions, the NEIDL's goals are to: (1) Recruit and develop a cadre of investigators and research staff with expertise in the scientific disciplines required to investigate the pathogenesis of emerging infectious diseases caused by category A, B and C agents, including collaborations within the university, in the United States, and internationally; (2) Develop animal models for the comparative study of these pathogens, mimicking as closely as possible the human disease process, and build capacity for the creation and use of relevant animal models and innovative veterinary research support; (3) Perform translational, preclinical and clinical research in animals and humans; (4) Develop the methodologies needed to advance the development and testing of vaccines, therapeutics and diagnostics for these agents; (5) Train the next generation of research scientists and related support personnel in the requirements to perform maximum containment research in a safe and secure environment;( 6) Maintain the flexibility needed to support a national response in the event of a biodefense emergency; (7) Establish a "safety first" environment for the conduct of all activities in the Institute. Since opening for research at the BSL-4 and ABSL-4 levels in 2018, NEIDL has rapidly moved forward to recruit additional faculty whose skills and interests both expand and complement existing expertise, bring innovative new insights and methodology to expand our scientific capabilities, open up research on new pathogens. In order to advance vaccines and therapeutics, the NEIDL has expanded its Regulatory Compliance Group and practices to permit studies to be carried out under Well- Documented practices. The NEIDL focuses on and supports innovative science, led by our faculty investigators, and as a result we also continue to evolve our integrated research support services to provide support needed for BSL-4 research to better reflect and provide access to new technology and research approaches, in order to remain at the leading edge of science.

全面的 抽象的 波士顿大学 (BU) 的国家生物防护实验室 (NBL) 被称为国家新兴实验室 传染病实验室 (NEIDL)。它由 BU 拥有和经营，位于波士顿 大学医学校区 (BUMC) 毗邻 BU 医学院、研究生科学研究项目、 波士顿大学公共卫生学院和附属教学医院波士顿医学中心。 NEIDL 的 使命是：（1）针对新发传染病开展创新基础、转化和临床研究 疾病，以开发诊断测试、治疗方法和疫苗，以促进公众健康； (2) 至 提供这些研究领域的培训，并支持国家在发生生物防御时采取的应对措施 紧急情况; (3) 建立一个高度关注社区和实验室的研究设施 安全和保障。为了成功实现这些使命，NEIDL 的目标是： (1) 招募和 培养一支由具有所需科学学科专业知识的调查人员和研究人员组成的骨干队伍 调查由A、B、C类病原体引起的新发传染病的发病机制，包括 大学内部、美国和国际上的合作； (2) 建立动物模型 对这些病原体进行比较研究，尽可能模仿人类疾病过程，并建立 创建和使用相关动物模型以及创新兽医研究支持的能力； (3) 对动物和人类进行转化、临床前和临床研究； (4) 制定方法论 需要推进这些药物的疫苗、治疗方法和诊断方法的开发和测试； (5) 培训下一代研究科学家和相关支持人员以满足执行要求 在安全可靠的环境中进行最大限度的遏制研究；（6）保持必要的灵活性 支持发生生物防御紧急情况时的国家应对措施； （七）营造“安全第一”的环境 以便开展研究所的所有活动。自 BSL-4 和 ABSL-4 级别的研究开放以来 2018 年，NEIDL 迅速招募了更多的教师，他们的技能和兴趣都在扩大和扩大 补充现有的专业知识，带来创新的新见解和方法来扩展我们的科学 能力，开辟新病原体的研究。为了推进疫苗和治疗方法的发展，NEIDL 已扩大其监管合规小组和实践，以允许在 Well- 下进行研究 记录的做法。 NEIDL 专注于并支持由我们的教师领导的创新科学 研究人员，因此我们还继续发展我们的综合研究支持服务，以提供 BSL-4 研究需要支持，以更好地反映和提供新技术和研究成果 方法，以保持在科学的前沿。

项目成果

Quantification of Viral and Host Biomarkers in the Liver of Rhesus Macaques: A Longitudinal Study of Zaire Ebolavirus Strain Kikwit (EBOV/Kik).

恒河猴肝脏中病毒和宿主生物标志物的定量：扎伊尔埃博拉病毒株 Kikwit (EBOV/Kik) 的纵向研究。

• 发表时间: 2020
• 作者: Greenberg, Alexandra;Huber, Bertrand R;Liu, David X;Logue, James P;Hischak, Amanda M W;Hart, Randy J;Abbott, Maureen;Isic, Nejra;Hisada, Yohei M;Mackman, Nigel;Bennett, Richard S;Hensley, Lisa E;Connor, John H;Crossland, Nicholas A
• 通讯作者: Crossland, Nicholas A

Design of universal Ebola virus vaccine candidates via immunofocusing.

通过免疫聚焦设计通用埃博拉病毒候选疫苗。

• 发表时间: 2024-02-13
• 影响因子: 11.1
• 作者: Xu, Duo;Powell, Abigail E;Utz, Ashley;Sanyal, Mrinmoy;Do, Jonathan;Patten, J J;Moliva, Juan I;Sullivan, Nancy J;Davey, Robert A;Kim, Peter S
• 通讯作者: Kim, Peter S

Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo.

通过体外和体内药理学评估和细胞网络定向优先排序相结合，鉴定 SARS-CoV-2 感染所需的可药物宿主靶点。

• 发表时间: 2022-02-01
• 作者: Patten, J J;Keiser, Patrick T;Gysi, Deisy;Menichetti, Giulia;Mori, Hiroyuki;Donahue, Callie J;Gan, Xiao;do Valle, Italo;Geoghegan;Anantpadma, Manu;Boytz, RuthMabel;Berrigan, Jacob L;Hulsey;Ayazika, Tess;O'Leary
• 通讯作者: O'Leary

Art of the Kill: Designing and Testing Viral Inactivation Procedures for Highly Pathogenic Negative Sense RNA Viruses.

杀戮的艺术：设计和测试高致病性负义 RNA 病毒的病毒灭活程序。

• 发表时间: 2023-07-19
• 作者: Olejnik, Judith;Hume, Adam J;Ross, Stephen J;Scoon, Whitney A;Seitz, Scott;White, Mitchell R;Slutzky, Ben;Yun, Nadezhda E;Mühlberger, Elke
• 通讯作者: Mühlberger, Elke

Science, not speculation, is essential to determine how SARS-CoV-2 reached humans.

对于确定 SARS-CoV-2 如何到达人类至关重要，科学而非推测。

• 发表时间: 2021-07-17
• 作者: Calisher, Charles H;Carroll, Dennis;Colwell, Rita;Corley, Ronald B;Daszak, Peter;Drosten, Christian;Enjuanes, Luis;Farrar, Jeremy;Field, Hume;Golding, Josie;Gorbalenya, Alexander E;Haagmans, Bart;Hughes, James M;Keusch, Gerald T;Lam, Sai Kit
• 通讯作者: Lam, Sai Kit